Home › Research › Biomarkers
Adaptation of a Protocol for Disclosure of Amyloid PET Results for Adults with Down Syndrome and Their Caregivers
Hayat M Sherif, Lindsay R. Clark, Nathaniel A. Chin, Sigan L. Hartley, Bradley T. Christian, Fred B. Ketchum. Alzheimer s & Dementia, 2025-12-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Adults with DS are often supported by family caregiver(s), who face challenges including lack of awareness of the increased risk of developing AD, difficulty in obtaining a timely diagnosis, limited resources for psychosocial support, and lack of access to clinical trials. We adapted materials to address the informational needs of dyads and adapted the disclosure protocol to focus on and assess the following: level of understanding of the biomarker results, concerns, and capacity to act on disclosure results and seek resources. Specific training was also provided to disclosing clinicians on the diagnosis of AD in adults with DS. To our knowledge this is the first adaptation of an amyloid PET disclosure protocol for adults with DS and their caregivers. This adaptation emphasizes empowering the dyad, and is a first step towards achieving equity in AD diagnosis and treatment for a population of individuals with Down Syndrome. In the next phase of research, we will further refine the protocol through pilot testing with adults with DS who have undergone amyloid PET scans as part of ABC-DS.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study. This work adapted an amyloid PET result disclosure protocol for adults with Down syndrome and their caregivers, the first such adaptation to the authors' knowledge. It is a first step toward equity in AD diagnosis and treatment for this population, with pilot testing planned next.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Sherif, H. M., Clark, L. R., Chin, N. A., Hartley, S. L., Christian, B. T., & Ketchum, F. B. (2025). Adaptation of a Protocol for Disclosure of Amyloid PET Results for Adults with Down Syndrome and Their Caregivers. Alzheimer s & Dementia. https://doi.org/10.1002/alz70858_100947
Vancouver
Sherif HM, Clark LR, Chin NA, Hartley SL, Christian BT, Ketchum FB. Adaptation of a Protocol for Disclosure of Amyloid PET Results for Adults with Down Syndrome and Their Caregivers. Alzheimer s & Dementia. 2025. doi:10.1002/alz70858_100947. PMID: 41448156.
BibTeX
@article{sherif2025-41448156,
author = {Sherif, Hayat M and Clark, Lindsay R. and Chin, Nathaniel A. and Hartley, Sigan L. and Christian, Bradley T. and Ketchum, Fred B.},
title = {{Adaptation of a Protocol for Disclosure of Amyloid PET Results for Adults with Down Syndrome and Their Caregivers}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70858_100947},
pmid = {41448156},
url = {https://doi.org/10.1002/alz70858_100947}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Adults with DS are often supported by family caregiver(s), who face challenges including lack of awareness of the increased risk of developing AD, difficulty in obtaining a timely diagnosis, limited resources for psychosocial support, and lack of access to clinical trials.
- We adapted materials to address the informational needs of dyads and adapted the disclosure protocol to focus on and assess the following: level of understanding of the biomarker results, concerns, and capacity to act on disclosure results and seek resources.
- Specific training was also provided to disclosing clinicians on the diagnosis of AD in adults with DS.
- To our knowledge this is the first adaptation of an amyloid PET disclosure protocol for adults with DS and their caregivers.
- This adaptation emphasizes empowering the dyad, and is a first step towards achieving equity in AD diagnosis and treatment for a population of individuals with Down Syndrome.
Why it matters
This work adapted an amyloid PET result disclosure protocol for adults with Down syndrome and their caregivers, the first such adaptation to the authors' knowledge. It is a first step toward equity in AD diagnosis and treatment for this population, with pilot testing planned next.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designlongitudinal study
- Evidence strengthModerate
How this study scored 40/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Fred B. Ketchum: h-index 6 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Wisconsin–Madison: institution h-index 1,518 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41448156) |
| Free to read | 2 / 2 | Free to read |
| Total | 40 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70858_100947
- PubMed: 41448156
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.